Interscope this week said it won FDA clearance for its EndoRotor System.
The system is a flexible microdebrider that is used in the digestive tract that reduces the need for surgery in recurrent adenoma and removal of walled-off necrosis. With the FDA clearance, the company hopes to expand into the pulmonary space.
“We are extremely excited to be able to offer this therapy, building on the efficacy of other microdebrider OEMs whose devices were limited to the central airway. EndoRotor provides customers with a means to access distal lesions using the proven concept of micro debridement. We are excited to continue to build on the success of introducing the first-ever flexible shaver for pulmonary procedures. We are continuing to propel advancements in interventional endoscopic and minimally invasive care,” CEO Jeffery Ryan said in a news release.
The company won FDA clearance for the device in 2018 for a gastroenterology indication.
